secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2024-05-16T23:59:59+00:00
Accession:  0001104659-24-062296
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune posts Q4 net loss $55.1M; RP1 melanoma BLA on track for 2H 2024
-------------------------------------------------------------------------

- Net loss of $55.1M for Q4 FY2024; full-year net loss $215.8M vs $174.3M prior year.
- Cash, equivalents & investments $420.7M; cash runway projected into 2H 2026.
- Primary analysis of IGNYTE trial (RP1 + nivolumab) in anti-PD1 failed melanoma expected Q2 2024.
- BLA submission for RP1 in anti-PD1 failed melanoma planned for 2H 2024 after positive FDA CMC meeting.
- First patient enrollment in Phase 3 IGNYTE-3 confirmatory trial expected 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465924062296/0001104659-24-062296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465924062296/tm2413978d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-062296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer